Company Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases.
It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.
The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma.
In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes.
Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza.
SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Samuel J. Reich |
Contact Details
Address: 777 W 41st St, Suite 401 Miami Beach, Florida 33140 United States | |
| Phone | 305-845-2813 |
| Website | sabbiotherapeutics.com |
Stock Details
| Ticker Symbol | SABS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001833214 |
| CUSIP Number | 78397T103 |
| ISIN Number | US78397T2024 |
| Employer ID | 85-3899721 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Samuel J. Reich | Chief Executive Officer and Executive Chairman |
| Dr. Eddie Joe Sullivan Ph.D. | Co-Founder, President and Director |
| Christine E. Hamilton M.B.A. | Co-Founder and Independent Director |
| Michael George King Jr. | Executive Vice President and Chief Financial Officer |
| Dr. Christoph Bausch M.B.A., Ph.D. | Executive Vice President and Chief Operating Officer |
| Dr. Alexandra Kropotova M.B.A., M.D. | Executive Vice President and Chief Medical Officer |
| Dr. Edward D. Hamilton D.V.M. | Co-Founder and Board Observer |
| Dr. Carlos N. Carillo Ph.D. | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 27, 2024 | 8-K | Current Report |
| May 31, 2024 | 8-K | Current Report |
| May 30, 2024 | DEF 14A | Other definitive proxy statements |
| May 21, 2024 | 8-K | Current Report |
| May 20, 2024 | 10-Q | Quarterly Report |
| May 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| May 8, 2024 | 8-K | Current Report |
| Apr 15, 2024 | 8-K | Current Report |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 29, 2024 | 10-K | Annual Report |